Idiosyncratic Drug-induced Liver Injury Study (DILIGEN)

The international Drug-induced Liver Injury Consortium (iDILIC), is studying the genetic susceptibility to idiosyncratic drug-induced liver injury. The UK arm of the study is DILIGEN. The study, involves collecting DNA from cases and suitable controls for a genome wide association study (GWAS) with the aim of identifying polymorphisms predictive of the development of drug-related liver injury and hence allowing the possibility of prevention. We will be grateful to physicians treating idiosyncratic drug-induced liver injury cases, particularly BSG members, to put us in contact with suitable patients.

Patients who developed one of the following due to drug-induced liver injury are suitable to be included:

  • >5-fold elevation above the upper limit of normal (ULN) of alanine transaminase (ALT) (or aspartate transaminase; AST when ALT is unavailable)
  • >2-fold elevation above the ULN for alkaline phosphatase (ALP) (when there is no bony cause for rise in ALP)
  • >3-fold elevation in ALT plus bilirubin elevation exceeding 2x UL

If any patients under your care either in the past or currently have suffered drug-induced liver injury relating to any prescribed drug, please contact our Research Nurse, Suzanne Henry, on the following telephone number: 0115 9249924 x 64415; Mobile Number 07595284870 or email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it .